Caspofungin: the first in a new class of antifungal agents (Q35214623)

7 August 2017

1 reference

title

Caspofungin: the first in a new class of antifungal agents (English)

1 reference

7 August 2017

Nicholas A Kartsonis

1

1 reference

7 August 2017

Jennifer Nielsen

series ordinal

2

1 reference

7 August 2017

Cameron M Douglas

series ordinal

3

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

published in

Drug Resistance Updates

1 reference

7 August 2017

volume

6

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

197-218

1 reference

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

A classification of nucleotide-diphospho-sugar glycosyltransferases based on amino acid sequence similarities

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

New drugs and novel targets for treatment of invasive fungal infections in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Fungal ß(1,3)-D-glucan synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Treatment of murine Candida krusei or Candida glabrata infection with L-743,872

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Treatment of murine disseminated candidiasis with L-743,872

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Treatment of histoplasmosis with MK-991 (L-743,872)

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Isolation of a gene involved in 1,3-beta-glucan synthesis in Aspergillus nidulans and purification of the corresponding protein

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Differential sensitivity between Fks1p and Fks2p against a novel beta -1,3-glucan synthase inhibitor, aerothricin3 [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Caspofungin: the first representative of a new antifungal class.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

1,3-beta-Glucan synthase: a useful target for antifungal drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Current and future approaches to antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Photoaffinity analog of the semisynthetic echinocandin LY303366: identification of echinocandin targets in Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Safety and tolerability of caspofungin acetate in the treatment of fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Echinocandin inhibition of 1,3-β-D-glucan synthase from Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Resolution of azole-resistant oesophageal candidiasis in an AIDS patient after treatment with caspofungin

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Resolution of multidrug-refractory oesophageal candidiasis in an AIDS patient after treatment with caspofungin

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

Resistance mechanisms in clinical isolates of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900064-5

7 January 2021

10.1016/S1368-7646(03)00064-5

Identifiers

DOI

1 reference

7 August 2017

1 reference